Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options to ten new employees, totaling 343,000 shares at an exercise price of $21.53, the closing price on November 9, 2020. This grant was made under the 2020 Inducement Plan, approved by the Board of Directors in January 2020, in line with NYSE rules. Arcus is focused on developing innovative cancer therapies and currently has four clinical candidates: Etrumadenant, AB680, Domvanalimab, and Zimberelimab, addressing significant cancer treatment gaps.
Arcus Biosciences (NYSE:RCUS) reported Q3 2020 financial results, revealing revenues of $64.5 million, a substantial increase from $1.8 million in Q3 2019, driven by collaboration with Gilead. The company holds $785 million in cash, expected to fund operations into 2023. R&D expenses grew to $51.8 million from $17.2 million due to increased clinical trial activities. Arcus anticipates significant clinical readouts in 2021, aiming for pivotal trials for its cancer therapies, including zimberelimab and domvanalimab.
Arcus Biosciences (NYSE:RCUS) has partnered with AstraZeneca to evaluate the investigational anti-TIGIT antibody, domvanalimab, in a Phase 3 clinical trial for unresectable Stage III non-small cell lung cancer (NSCLC), using Imfinzi as a combination therapy. The collaboration aims to enhance efficacy and long-term survival rates in NSCLC patients, building on promising data from previous trials. AstraZeneca will lead the trial while both companies share costs and maintain rights to their respective therapies.
Arcus Biosciences, Inc. (NYSE:RCUS) has granted stock options to 17 new employees to purchase a total of 559,000 shares at an exercise price of $19.20, reflecting the closing price on October 8, 2020. This issuance falls under the 2020 Inducement Plan, which was approved by the Board of Directors. The company focuses on developing innovative cancer therapies, with four molecules in clinical trials targeting various cancers, including Etrumadenant and AB680.
Arcus Biosciences (NYSE:RCUS) announced the return of Jennifer Jarrett as Chief Operating Officer, overseeing commercial and administrative operations. Jarrett, who previously helped lead the company's IPO, brings extensive experience in healthcare and finance. CEO Terry Rosen emphasized her role in facilitating Arcus's mission to develop transformative cancer therapies, especially with three molecules potentially entering registrational trials. In conjunction with her appointment, Jarrett received options to purchase 900,000 shares at $17.17 each, part of an inducement grant approved by the board.